-$0.37 Earnings Per Share Expected for ASLAN PHARMACEU/ADR (ASLN) This Quarter
Brokerages expect ASLAN PHARMACEU/ADR (NASDAQ:ASLN) to report earnings per share (EPS) of ($0.37) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for ASLAN PHARMACEU/ADR’s earnings, with estimates ranging from ($0.38) to ($0.35). The business is scheduled to announce its next quarterly earnings report on Monday, January 1st.
On average, analysts expect that ASLAN PHARMACEU/ADR will report full year earnings of ($1.41) per share for the current year, with EPS estimates ranging from ($1.42) to ($1.40). For the next year, analysts forecast that the company will report earnings of ($1.29) per share, with EPS estimates ranging from ($1.74) to ($0.97). Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that cover ASLAN PHARMACEU/ADR.
ASLAN PHARMACEU/ADR (NASDAQ:ASLN) last released its quarterly earnings data on Thursday, November 8th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.27.
NASDAQ ASLN opened at $3.47 on Friday. ASLAN PHARMACEU/ADR has a 1-year low of $2.51 and a 1-year high of $10.44.
An institutional investor recently bought a new position in ASLAN PHARMACEU/ADR stock. FNY Investment Advisers LLC purchased a new position in shares of ASLAN PHARMACEU/ADR (NASDAQ:ASLN) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 26,402 shares of the company’s stock, valued at approximately $104,000. FNY Investment Advisers LLC owned approximately 0.08% of ASLAN PHARMACEU/ADR as of its most recent filing with the Securities and Exchange Commission. 10.95% of the stock is owned by hedge funds and other institutional investors.
ASLAN PHARMACEU/ADR Company Profile
ASLAN Pharmaceuticals Limited, a clinical-stage oncology-focused biopharmaceutical company, engages in developing therapeutics for global markets. It targets diseases that are highly prevalent in Asia, and orphan indications in the United States and Europe. The company's product pipeline includes Varlitinib, a reversible small molecule pan-human epidermal growth factor receptor inhibitor that is being studied in global pivotal trials (TreeTopp) for biliary tract cancer, and conducting Phase 2/3 clinical trials for gastric cancer, as well as testing in a single-arm pivotal clinical trial in biliary tract cancer in China.
See Also: Understanding Analyst Ratings
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ASLAN PHARMACEU/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASLAN PHARMACEU/ADR and related companies with MarketBeat.com's FREE daily email newsletter.